Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
212 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteoarthritis Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2016, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape. Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 19, 6, 1, 17, 5 and 1 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Osteoarthritis Pain. Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Osteoarthritis Pain Overview 7 Therapeutics Development 8 Osteoarthritis Pain - Therapeutics under Development by Companies 10 Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 13 Osteoarthritis Pain - Pipeline Products Glance 14 Osteoarthritis Pain - Products under Development by Companies 18 Osteoarthritis Pain - Products under Investigation by Universities/Institutes 22 Osteoarthritis Pain - Companies Involved in Therapeutics Development 23 Osteoarthritis Pain - Therapeutics Assessment 62 Drug Profiles 77 Osteoarthritis Pain - Dormant Projects 187 Osteoarthritis Pain - Discontinued Products 192 Osteoarthritis Pain - Product Development Milestones 194 Appendix 204
List of Tables
Number of Products under Development for Osteoarthritis Pain, H2 2016 15 Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Development by Companies, H2 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Osteoarthritis Pain - Pipeline by AbbVie Inc, H2 2016 30 Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2016 31 Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 32 Osteoarthritis Pain - Pipeline by Akron Molecules AG, H2 2016 33 Osteoarthritis Pain - Pipeline by Allergan Plc, H2 2016 34 Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 35 Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016 36 Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc., H2 2016 37 Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 38 Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H2 2016 39 Osteoarthritis Pain - Pipeline by AskAt Inc., H2 2016 40 Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H2 2016 41 Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H2 2016 42 Osteoarthritis Pain - Pipeline by Biogen Inc, H2 2016 43 Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016 44 Osteoarthritis Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 45 Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 46 Osteoarthritis Pain - Pipeline by Chromocell Corporation, H2 2016 47 Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H2 2016 48 Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016 49 Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc., H2 2016 50 Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H2 2016 51 Osteoarthritis Pain - Pipeline by Genzyme Corporation, H2 2016 52 Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H2 2016 53 Osteoarthritis Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 54 Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H2 2016 55 Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016 56 Osteoarthritis Pain - Pipeline by Medestea Research & Production S.p.A., H2 2016 57 Osteoarthritis Pain - Pipeline by MedImmune, LLC, H2 2016 58 Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc., H2 2016 59 Osteoarthritis Pain - Pipeline by Pfizer Inc., H2 2016 60 Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H2 2016 61 Osteoarthritis Pain - Pipeline by pSivida Corp., H2 2016 62 Osteoarthritis Pain - Pipeline by Purdue Pharma LP, H2 2016 63 Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 64 Osteoarthritis Pain - Pipeline by Symic Biomedical, Inc., H2 2016 65 Osteoarthritis Pain - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 66 Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 67 Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 68 Assessment by Monotherapy Products, H2 2016 69 Assessment by Combination Products, H2 2016 70 Number of Products by Stage and Target, H2 2016 72 Number of Products by Stage and Mechanism of Action, H2 2016 76 Number of Products by Stage and Route of Administration, H2 2016 81 Number of Products by Stage and Molecule Type, H2 2016 83 Osteoarthritis Pain - Dormant Projects, H2 2016 194 Osteoarthritis Pain - Dormant Projects (Contd..1), H2 2016 195 Osteoarthritis Pain - Dormant Projects (Contd..2), H2 2016 196 Osteoarthritis Pain - Dormant Projects (Contd..3), H2 2016 197 Osteoarthritis Pain - Dormant Projects (Contd..4), H2 2016 198 Osteoarthritis Pain - Discontinued Products, H2 2016 199 Osteoarthritis Pain - Discontinued Products (Contd..1), H2 2016 200
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
